Karin Rathgen

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

Joachim Stangier, Karin Rathgen, Hildegard Stähle et al. · British Journal of Clinical Pharmacology · 2007 · 880 citations · Full text

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

Joachim Stangier, Karin Rathgen, Hildegard Stähle et al. · Clinical Pharmacokinetics · 2010 · 721 citations

Oral Dabigatran Etexilate, Pharmacological Study, Medicine +6

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

Joachim Stangier, Hildegard Stähle, Karin Rathgen et al. · Clinical Pharmacokinetics · 2008 · 421 citations

Thrombosis, Cardiovascular Disease, Healthy Elderly Subjects +7

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Joachim Stangier, Bengt I. Eriksson, Ola E. Dahl et al. · The Journal of Clinical Pharmacology · 2005 · 290 citations

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

Joachim Stangier, Hildegard Stähle, Karin Rathgen et al. · The Journal of Clinical Pharmacology · 2008 · 172 citations

Dabigatran Etexilate, Pathology, Moderate Hepatic Impairment +18